Hematología y Hemoterapia

Resultados: 408
Tipo Título / Nombre Autor(es) Año
COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330) Rosenberg A, Baljevic M, Alegre Amor A..., Bergua Burgues JM 2023
COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/MLL1 Rearrangements, NPM1 Mutation), DLBCL, MM, and CLL/SLL (NCT05153330) Ravandi F, Lancet J..., Bergua Burgues JM 2023
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ..., Casas Avilés I, et al 2023
Thrombotic profile of a serie of 14 patients carrying 67ARG>STOP polymorphism in the Serpine A10 (protase-dependent protein Z inhibitor) gene Bermejo N, Casado Cabanillas V, González Valero JM, Higuero V, Ibañez Espacio F 2023
Feasibility and outcome after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia. Results of the BURKIMAB14 trial Ribera JM, Morgades M, García Calduch O..., Bergua Burgues JM 2023
Mezigdomide (MEZI) Plus Dexamethasone (DEX) in patients (PTS) with relapsed/refractory multiple myeloma (RRMM): results from the dose-expansion phase of the CC-92480-MM trial Bahlis N, Trudel S, Quach H..., Casas-Aviles I 2023
Midostaurin plus 7+3 or Quizartinib plus 7+3 in FLT3-ITD mutated AML Torno M, Día Beya M, Fenández Moreno A..., Bergua Burgues JM 2023
Incidence, risk factors and outcomes od second neoplasm in patients with acute promyelocytic leukemia: the PETHEMA -PALG experience Sobas M, Knopinska-Posluszny W, Bergua Burgues JM, Rodríguez-Veiga R, Cano Ferri I..., Montesinos P, et al 2023
Update results of VEN-A-QUI study: a phase 1-2 trial to assess the safety and efficacy of triplets for newly diagnosed unfit AML patients: Azacitidine or low-dose Cytarabline with Venetoclax and Quizartinib Bergua Burgués JM, Rodríguez-Veiga R, Cano Ferri I..., Montesinos P 2023
Preliminary results of QUIWI: a double blinded, randomized clinical trial comparing standard chemotherapy plus quizartinib versus placebo in adult patients with newly diagnosed FLT3-ITD wild- type AML Montesinos P, Rodríquez-Veiga R, Bergua Burgues JM, Algarra L..., Labrador J 2023